Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test [NA]
Results of a completed clinical trial evaluating at-home monitoring of exercise capacity using an app-based 6-minute walk test in patients w…
-
EMA approval · 2026-07-27EMA Authorised: Macitentan AccordPharma (macitentan) — Accord Healthcare
Macitentan AccordPharma has been authorized for use, with the therapeutic areas listed as hypertension and pulmonary disease.
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Results: Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects [Phase 3]
Phase 3 trial evaluating ralinepag on exercise capacity in pulmonary arterial hypertension; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Results: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). [Phase 2]
A Phase 2 trial evaluating KER-012 in combination with background therapy for adult pulmonary arterial hypertension was terminated; results …
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH [Phase 4]
Phase 4 trial results on riociguat evaluating effects on right ventricular size and function in patients with primary pulmonary arterial hyp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study [Phase 2]
Phase 2B trial results of inhaled vardenafil for pulmonary arterial hypertension have been completed and results posted.
-
EMA approval · 2026-06-11EMA Authorised: Winrevair — Merck Sharp & Dohme B.V.
Winrevair has been authorised by EMA, with therapeutic area listed as Hypertension and Pulmonary; orphan medicine designation.
-
EMA approval · 2026-06-05EMA Authorised: Opsumit (macitentan) — Janssen-Cilag International N.V.
Opsumit (macitentan) has been authorised in the EU for pulmonary arterial hypertension as a new therapeutic option.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension [Phase 3]
Phase 3 outcome study evaluating a 75 mg dose of macitentan in patients with pulmonary arterial hypertension; status active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial investigating selexipag as add-on therapy to standard of care in children with pulmonary arterial hypertension; status ACTIVE_…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) [Phase 3]
Phase 3 trial update on seralutinib in adults with pulmonary arterial hypertension reports efficacy and safety results.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) [Phase 3]
Open-label extension study update for seralutinib in adults with pulmonary arterial hypertension (PAH) continuing from a Phase 3 program.
-
CLINICAL_TRIALS withdrawal · 2026-04-27Clinical Trial Update: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) [Phase 3]
Phase 3 study of sotatercept in newly diagnosed intermediate- and high-risk pulmonary arterial hypertension was terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Results: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) [Phase 3]
Phase 3 trial of sotatercept (MK-7962) in newly diagnosed intermediate- and high-risk pulmonary arterial hypertension was terminated with re…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Spironolactone for Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 clinical trial evaluating spironolactone for pulmonary arterial hypertension is currently recruiting.
-
CLINICAL_TRIALS other · 2026-04-24Clinical Trial Update: Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires [NA]
The NHLBI-supported trial on MRI-guided heart catheterization using passive guidewires has been suspended; the study targets patients with p…
-
EMA approval · 2026-04-23EMA Authorised: Opsumit (macitentan) — Janssen-Cilag International N.V.
EMA authorised Opsumit (macitentan) by Janssen-Cilag International N.V. for pulmonary arterial hypertension. This marks EU authorization of …
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 clinical trial is evaluating the safety and tolerability of artesunate in patients with Pulmonary Arterial Hypertension. The study…
-
EMA approval · 2026-04-22EMA Authorised: Volibris (ambrisentan) — GlaxoSmithKline Trading Services Limited
EMA authorised Volibris (ambrisentan) for pulmonary arterial hypertension; the marketing authorisation holder is GlaxoSmithKline Trading Ser…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension [Phase 1, Phase 2]
Pfizer is conducting a Phase 1/Phase 2 study to evaluate PF-07868489 in healthy adults and in patients with pulmonary arterial hypertension.…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 study evaluating REGN13335 in adults with pulmonary arterial hypertension is currently recruiting.
-
CLINICAL_TRIALS other · 2026-04-21Clinical Trial Update: A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 [Phase 2]
A Phase 2 study to evaluate PF-07868489 in people with pulmonary arterial hypertension, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Study of Intravenous ZMA001 in Healthy Subjects [Phase 1]
Phase 1 study evaluating intravenous ZMA001 in healthy subjects to characterize safety, tolerability, and pharmacokinetics, with the trial l…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) [Phase 3]
This update describes a Phase 3 study of Sotatercept (MK-7962) for pulmonary arterial hypertension. The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Pulmonary Hypertension Peripheral Limitations [NA]
A Mayo Clinic clinical trial studying pulmonary hypertension, including pulmonary arterial hypertension patients and healthy volunteers, is …